Journal of Molecular Medicine

, Volume 85, Issue 8, pp 863–875 | Cite as

Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma

  • Xiao-Li Du
  • Hai Hu
  • De-Chen Lin
  • Shu-Hua Xia
  • Xiao-Ming Shen
  • Yu Zhang
  • Man-Li Luo
  • Yan-Bin Feng
  • Yan Cai
  • Xin Xu
  • Ya-Ling Han
  • Qi-Min Zhan
  • Ming-Rong WangEmail author
Original Article


Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer death in China. In the present study, proteins in tumors and adjacent normal esophageal tissues from 41 patients with ESCC were extracted, and two-dimensional electrophoresis (2-DE) was performed using the pH 3–10 and 4–7 immobilized pH gradient strips. The protein spots expressed differentially between tumors and normal tissues were identified by matrix-assisted laser desorption/ionization and liquid chromatography electrospray/ionization ion trap mass spectrometry. A total of 22 proteins differentially expressed between ESCC and normal esophageal tissues were identified, in which 17 proteins were upregulated and 5 downregulated in tumors. Biological functions of these proteins are related to cell signal transduction, cell proliferation, cell motility, glycolysis, regulation of transcription, oxidative stress processes, and protein folding. Some of the proteins obtained were confirmed by Western blotting and immunohistochemical staining. We showed that high expression of calreticulin and 78-kDa glucose-regulated protein (GRP78) were correlated with poor prognosis by Kaplan–Meier analysis and log rank analysis. Zinc finger protein 410, annexin V, similar to the ubiquitin-conjugating enzyme E2 variant 1 isoform c, mutant hemoglobin beta chain, TPM4–ALK fusion oncoprotein type 2, similar to heat shock congnate 71-kDa protein, GRP78, and pyruvate kinase M2 (M2–PK) were for the first time observed to be dysregulated in human ESCC tissues. The proteins here identified will contribute to the understanding of the tumorigenesis and progression of Chinese ESCC and may potentially provide useful markers for diagnosis or targets for therapeutic intervention and drug development.


Esophageal squamous cell carcinoma Proteomics Immunohistochemistry Two-dimensional electrophoresis (2-DE) Mass spectrometry (MS) 



This study was supported by the State Key Basic Research grant of China (2001CB510208, 2002CB513101, 2004CB518705), Beijing Science Fund (7042038), Specialized Research Fund for the Doctoral Program of Higher Education of China (20050023046), and Program for Changjiang Scholars and Innovative Research Team in University (IRT0416).


  1. 1.
    Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, Hazama S, Hirazawa K, Hayashi H, Tangoku A, Hirose K, Ishihara T, Suzuki T (1996) Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 56:2776–2780PubMedGoogle Scholar
  2. 2.
    Kwong KF (2005) Molecular biology of esophageal cancer in the genomics era. Surg Clin North Am 85:539–553PubMedCrossRefGoogle Scholar
  3. 3.
    Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241–2252PubMedCrossRefGoogle Scholar
  4. 4.
    Imazawa M, Hibi K, Fujitake S, Kodera Y, Ito K, Akiyama S, Nakao A (2005) S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma. Anticancer Res 25:1247–1250PubMedGoogle Scholar
  5. 5.
    Xiong XD, Xu LY, Shen ZY, Cai WJ, Luo JM, Han YL, Li EM (2002) Identification of differentially expressed proteins between human esophageal immortalized and carcinomatous cell lines by two-dimensional electrophoresis and MALDI–TOF-mass spectrometry. World J Gastroenterol 8:777–781PubMedGoogle Scholar
  6. 6.
    Yoshitake Y, Nakatsura T, Monji M, Senju S, Matsuyoshi H, Tsukamoto H, Hosaka S, Komori H, Fukuma D, Ikuta Y, Katagiri T, Furukawa Y, Ito H, Shinohara M, Nakamura Y, Nishimura Y (2004) Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res 10:6437–6448PubMedCrossRefGoogle Scholar
  7. 7.
    Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–S15PubMedCrossRefGoogle Scholar
  8. 8.
    Kavallaris M, Marshall GM (2005) Proteomics and disease: opportunities and challenges. Med J Aust 182:575–579PubMedGoogle Scholar
  9. 9.
    Bae SM, Lee CH, Cho YL, Nam KH, Kim YW, Kim CK, Han BD, Lee YJ, Chun HJ, Ahn WS (2005) Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecol Oncol 99:26–35PubMedCrossRefGoogle Scholar
  10. 10.
    Lexander H, Palmberg C, Auer G, Hellstrom M, Franzen B, Jornvall H, Egevad L (2005) Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol 27:263–272PubMedGoogle Scholar
  11. 11.
    Hwa JS, Kim HJ, Goo BM, Park HJ, Kim CW, Chung KH, Park HC, Chang SH, Kim YW, Kim DR, Cho GJ, Choi WS, Kang KR (2006) The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma. Proteomics 6:1077–1084PubMedCrossRefGoogle Scholar
  12. 12.
    Tomlinson AJ, Hincapie M, Morris GE, Chicz RM (2002) Global proteome analysis of a human gastric carcinoma. Electrophoresis 23:3233–3240PubMedCrossRefGoogle Scholar
  13. 13.
    Li C, Chen Z, Xiao Z, Wu X, Zhan X, Zhang X, Li M, Li J, Feng X, Liang S, Chen P, Xie JY (2003) Comparative proteomics analysis of human lung squamous carcinoma. Biochem Biophys Res Commun 309:253–260PubMedCrossRefGoogle Scholar
  14. 14.
    Beranova-Giorgianni S, Desiderio DM (2000) Mass spectrometry of the human pituitary proteome: identification of selected proteins. Rapid Commun Mass Spectrom 14:161–167PubMedCrossRefGoogle Scholar
  15. 15.
    Chang YS, Wu W, Walsh G, Hong WK, Mao L (2003) Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res 9:3641–3644PubMedGoogle Scholar
  16. 16.
    Li C, Xiao Z, Chen Z, Zhang X, Li J, Wu X, Li X, Yi H, Li M, Zhu G, Liang S (2006) Proteome analysis of human lung squamous carcinoma. Proteomics 6:547–558PubMedCrossRefGoogle Scholar
  17. 17.
    Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Fujimoto M, Nishisaka T, Okita K, Oka M, Nakamura K (2005) Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 5:1686–1692PubMedCrossRefGoogle Scholar
  18. 18.
    Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L (2002) Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis 19:319–326PubMedCrossRefGoogle Scholar
  19. 19.
    Qi Y, Chiu JF, Wang L, Kwong DL, He QY (2005) Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 5:2960–2971PubMedCrossRefGoogle Scholar
  20. 20.
    Benanti JA, Williams DK, Robinson KL, Ozer HL, Galloway DA (2002) Induction of extracellular matrix-remodeling genes by the senescence-associated protein APA-1. Mol Cell Biol 22:7385–7397PubMedCrossRefGoogle Scholar
  21. 21.
    Murray GI, Duncan ME, O’Neil P, Melvin WT, Fothergill JE (1996) Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2:461–462PubMedCrossRefGoogle Scholar
  22. 22.
    Ito T, Ito M, Shiozawa J, Naito S, Kanematsu T, Sekine I (1999) Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol 12:669–674PubMedGoogle Scholar
  23. 23.
    Inoue T, Yashiro M, Nishimura S, Maeda K, Sawada T, Ogawa Y, Sowa M, Chung KH (1999) Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med 4:73–77PubMedGoogle Scholar
  24. 24.
    Nakopoulou L, Giannopoulou I, Gakiopoulou H, Liapis H, Tzonou A, Davaris PS (1999) Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 30:436–442PubMedCrossRefGoogle Scholar
  25. 25.
    Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R, Terakawa N, Nakamura Y (1999) Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res 59:4225–4227PubMedGoogle Scholar
  26. 26.
    Nishioka Y, Kobayashi K, Sagae S, Ishioka S, Nishikawa A, Matsushima M, Kanamori Y, Minaguchi T, Nakamura Y, Tokino T, Kudo R (2000) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res 91:612–615PubMedGoogle Scholar
  27. 27.
    Murray GI, Duncan ME, O’Neil P, McKay JA, Melvin WT, Fothergill JE (1998) Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 185:256–261PubMedCrossRefGoogle Scholar
  28. 28.
    Yamashita K, Mori M, Kataoka A, Inoue H, Sugimachi K (2001) The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 84:276–282PubMedCrossRefGoogle Scholar
  29. 29.
    Fernandez PM, Tabbara SO, Jacobs LK, Manning FC, Tsangaris TN, Schwartz AM, Kennedy KA, Patierno SR (2000) Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 59:15–26PubMedCrossRefGoogle Scholar
  30. 30.
    Gazit G, Lu J, Lee AS (1999) De-regulation of GRP stress protein expression in human breast cancer cell lines. Breast Cancer Res Treat 54:135–146PubMedCrossRefGoogle Scholar
  31. 31.
    Koomagi R, Mattern J, Volm M (1999) Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LRP56 and angiogenesis in non-small cell lung carcinomas. Anticancer Res 19:4333–4336PubMedGoogle Scholar
  32. 32.
    Song MS, Park YK, Lee JH, Park K (2001) Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C-epsilon/ERK/AP-1 signaling cascade. Cancer Res 61:8322–8330PubMedGoogle Scholar
  33. 33.
    Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K, Hada A, Arai M, Wakatsuki T, Matsubara O, Yamamoto N, Yamamoto M (2003) Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol 38:605–614PubMedCrossRefGoogle Scholar
  34. 34.
    Misra UK, Deedwania R, Pizzo SV (2005) Binding of activated alpha2–macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK. J Biol Chem 280:26278–26286PubMedCrossRefGoogle Scholar
  35. 35.
    Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W, Pasqualini R (2004) Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cells 6:275–284CrossRefGoogle Scholar
  36. 36.
    Chen X, Ding Y, Liu CG, Mikhail S, Yang CS (2002) Overexpression of glucose-regulated protein 94 (Grp94) in esophageal adenocarcinomas of a rat surgical model and humans. Carcinogenesis 23:123–130PubMedCrossRefGoogle Scholar
  37. 37.
    Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T, Morita M, Yasumoto K (2005) Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49:55–62PubMedCrossRefGoogle Scholar
  38. 38.
    Lee KA, Shim JH, Kho CW, Park SG, Park BC, Kim JW, Lim JS, Choe YK, Paik SG, Yoon DY (2004) Protein profiling and identification of modulators regulated by the E7 oncogene in the C33A cell line by proteomics and genomics. Proteomics 4:839–848PubMedCrossRefGoogle Scholar
  39. 39.
    Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ, Caprioli RM (2004) Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 4:793–811PubMedCrossRefGoogle Scholar
  40. 40.
    Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, Sanchez JC, Frutiger S, Hughes G, Pallini V, Hochstrasser DF, Tosi P (1997) Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18:2832–2841PubMedCrossRefGoogle Scholar
  41. 41.
    Chahed K, Kabbage M, Ehret-Sabatier L, Lemaitre-Guillier C, Remadi S, Hoebeke J, Chouchane L (2005) Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and MALDI–TOF-mass spectrometry analyses. Int J Oncol 27:1425–1431PubMedGoogle Scholar
  42. 42.
    Alaiya A, Roblick U, Egevad L, Carlsson A, Franzen B, Volz D, Huwendiek S, Linder S, Auer G (2000) Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol 21:1–9PubMedGoogle Scholar
  43. 43.
    Nishimori T, Tomonaga T, Matsushita K, Oh-Ishi M, Kodera Y, Maeda T, Nomura F, Matsubara H, Shimada H, Ochiai T (2006) Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics 6:1011–1018PubMedCrossRefGoogle Scholar
  44. 44.
    Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, Yoshimura K, Terai A, Arai Y, Yoshiki T (2004) Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 50:857–866PubMedCrossRefGoogle Scholar
  45. 45.
    Li C, Hong Y, Tan YX, Zhou H, Ai JH, Li SJ, Zhang L, Xia QC, Wu JR, Wang HY, Zeng R (2004) Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol Cell Proteomics 3:399–409PubMedCrossRefGoogle Scholar
  46. 46.
    Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, Zhao R, Puravs E, Tra J, Michael CW, Misek DE, Hanash SM (2003) Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 278:7607–7616PubMedCrossRefGoogle Scholar
  47. 47.
    Johnson RJ, Liu N, Shanmugaratnam J, Fine RE (1998) Increased calreticulin stability in differentiated NG-108-15 cells correlates with resistance to apoptosis induced by antisense treatment. Brain Res Mol Brain Res 53:104–111PubMedCrossRefGoogle Scholar
  48. 48.
    Prasad GL, Valverius EM, McDuffie E, Cooper HL (1992) Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 3:507–513PubMedGoogle Scholar
  49. 49.
    Mazurek S, Boschek CB, Hugo F, Eigenbrodt E (2005) Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15:300–308PubMedCrossRefGoogle Scholar
  50. 50.
    Wechsel HW, Petri E, Bichler KH, Feil G (1999) Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2–PK). Anticancer Res 19:2583–2590PubMedGoogle Scholar
  51. 51.
    Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L (2004) Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 49:1149–1155PubMedCrossRefGoogle Scholar
  52. 52.
    Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G, Eigenbrodt E (2002) Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 22:311–318PubMedGoogle Scholar
  53. 53.
    Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K (2000) Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 20:5077–5082PubMedGoogle Scholar
  54. 54.
    Kaura B, Bagga R, Patel FD (2004) Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2–PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res 30:193–196PubMedCrossRefGoogle Scholar
  55. 55.
    Schneider J, Schulze G (2003) Comparison of tumor M2-pyruvate kinase (tumor M2–PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 23:5089–5093PubMedGoogle Scholar
  56. 56.
    Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU (2003) Measurement of fecal pyruvate kinase type M2 (tumor M2–PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 23:851–853PubMedGoogle Scholar
  57. 57.
    Schulze G (2000) The tumor marker tumor M2–PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res 20:4961–4964PubMedGoogle Scholar
  58. 58.
    Koss K, Harrison RF, Gregory J, Darnton SJ, Anderson MR, Jankowski JA (2004) The metabolic marker tumour pyruvate kinase type M2 (tumour M2–PK) shows increased expression along the metaplasia–dysplasia–adenocarcinoma sequence in Barrett’s oesophagus. J Clin Pathol 57:1156–1159PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Xiao-Li Du
    • 1
  • Hai Hu
    • 1
  • De-Chen Lin
    • 1
  • Shu-Hua Xia
    • 1
  • Xiao-Ming Shen
    • 1
  • Yu Zhang
    • 1
  • Man-Li Luo
    • 1
  • Yan-Bin Feng
    • 1
  • Yan Cai
    • 1
  • Xin Xu
    • 1
  • Ya-Ling Han
    • 1
  • Qi-Min Zhan
    • 1
  • Ming-Rong Wang
    • 1
    Email author
  1. 1.State Key Laboratory of Molecular Oncology, Cancer Institute (Hospital)Peking Union Medical College, Chinese Academy of Medical SciencesBeijingPeople’s Republic of China

Personalised recommendations